Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure

Mengying ZHU; Ping YU; Guohong GE; Yuqi MA; Xiling FU; Jiabao CHANG

doi:10.12449/JCH241112

Volume 40 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(11): 2201-2204

PDF( 691 KB)

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure

DOI: 10.12449/JCH241112

1.
Department of Hepatology，Nanjing Second Hospital，Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine，Nanjing 210003，China
2.
Department of Hepatology，Wuxi Fifth People’s Hospital，Wuxi，Jiangsu 214011，China
3.
Department of Hepatology，The Third People’s Hospital of Zhenjiang，Zhenjiang，Jiangsu 212021，China

More Information

Corresponding author: CHANG Jiabao， chang_jiabao@126.com （ORCID： 0000-0003-3209-4868）
Received Date: 2024-02-22
Accepted Date: 2024-04-16
Published Date: 2024-11-25

Abstract

Abstract

Objective To investigate the efficacy and safety of sofosbuvir/velpatasivr/voxilaprevir （SOF/VEL/VOX） in patients with HCV infection experiencing failure in previous direct-acting antiviral agent （DAA） therapy. Methods A retrospective analysis was performed for the chronic hepatitis C patients who experienced failure in previous DAA antiviral therapy and were treated with SOF/VEL/VOX （400 mg/100 mg/100 mg/tablet， 1 tablet/day） for 12 weeks in Nanjing Second Hospital， Wuxi Fifth People’s Hospital， and The Third People’s Hospital of Zhenjiang from June 2020 to June 2023. Sustained virological response at 12 weeks （SVR12） was observed after the end of treatment， and the changes in biochemical parameters and the incidence rate of adverse reactions were assessed to evaluate drug safety. The paired t-test was used for comparison of continuous data between two groups. Results A total of 36 patients were enrolled， among whom there were 27 non-liver cirrhosis patients and 9 patients with compensated liver cirrhosis， and 4 patients experienced failure in the previous two or more sessions of DAA therapy. Two patients were lost to follow-up after treatment， and the remaining 34 patients （34/36， 94.4%） achieved SVR12. Among the 36 patients enrolled， the most common adverse events were pruritus， nausea， fatigue， and headache， and one patient （2.78%） experienced serious adverse events； there were no adverse events that resulted in the discontinuation of therapeutic agents or the death of patients. Conclusion For chronic hepatitis C patients who experience failure in previous DAA therapy， SOF/VEL/VOX salvage therapy has a relatively high rate of SVR12， with good tolerability and safety.
- Hepatitis C， Chronic,
- Salvage Therapy,
- Sofosbuvir,
- Velpatasvir,
- Voxilaprevir

FullText(HTML)

References(18)

References

[1]	Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6.
[2]	MANGIA A, MILLIGAN S, KHALILI M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts[J]. Liver Int, 2020, 40( 8): 1841- 1852. DOI: 10.1111/liv.14537.
[3]	XIAO L, ZHANG LY. Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b[J]. Int J Virol, 2023, 30( 5): 423- 428. DOI: 10.3760/cma.j.issn.1673-4092.2023.05.017. 肖琳, 张岭漪. 艾尔巴韦/格拉瑞韦治疗中国1b型慢性丙型肝炎患者的疗效和安全性[J]. 国际病毒学杂志, 2023, 30( 5): 423- 428. DOI: 10.3760/cma.j.issn.1673-4092.2023.05.017.
[4]	BOURLIÈRE M, GORDON SC, FLAMM SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection[J]. N Engl J Med, 2017, 376( 22): 2134- 2146. DOI: 10.1056/NEJMoa1613512.
[5]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 428- 447. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.002.
[6]	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. J Hepatol, 2020, 73( 5): 1170- 1218. DOI: 10.1016/j.jhep.2020.08.018.
[7]	RAO HY. Key points in hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection[J]. J Clin Hepatol, 2023, 39( 12): 2798- 2803. DOI: 10.3969/j.issn.1001-5256.2023.12.008. 饶慧瑛.《美国肝病学会/美国感染病学会丙型肝炎指导意见: HCV感染的检测、管理和治疗(2023年更新)》意见要点[J]. 临床肝胆病杂志, 2023, 39( 12): 2798- 2803. DOI: 10.3969/j.issn.1001-5256.2023.12.008.
[8]	JI FP, LI J, LIU L, et al. High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b[J]. J Gastroenterol Hepatol, 2021, 36( 3): 767- 774. DOI: 10.1111/jgh.15192.
[9]	CHEN CY, HUANG CF, CHENG PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan[J]. Liver Int, 2021, 41( 6): 1265- 1277. DOI: 10.1111/liv.14849.
[10]	MENDIZABAL M, PINERO F, RIDRUEJO E, et al. Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents[J]. Clin Gastroenterol Hepatol, 2020, 18( 11): 2554- 2563. e 3. DOI: 10.1016/j.cgh.2020.02.044.
[11]	CARRAT F, FONTAINE H, DORIVAL C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study[J]. Lancet, 2019, 393( 10179): 1453- 1464. DOI: 10.1016/S0140-6736(18)32111-1.
[12]	BACKUS LI, BELPERIO PS, SHAHOUMIAN TA, et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease[J]. Hepatology, 2019, 69( 2): 487- 497. DOI: 10.1002/hep.29408.
[13]	HONG CM, LIN YY, LIU CJ, et al. Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan[J]. Viruses, 2021, 13( 11): 2294. DOI: 10.3390/v13112294.
[14]	BELPERIO PS, SHAHOUMIAN TA, LOOMIS TP, et al. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients[J]. J Viral Hepat, 2019, 26( 8): 980- 990. DOI: 10.1111/jvh.13115.
[15]	PAPALUCA T, ROBERTS SK, STRASSER SI, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus(HCV) NS5A-inhibitor experienced patients with difficult to cure characteristics[J]. Clin Infect Dis, 2021, 73( 9): e3288- e3295. DOI: 10.1093/cid/ciaa1318.
[16]	LLANERAS J, RIVEIRO-BARCIELA M, LENS S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs[J]. J Hepatol, 2019, 71( 4): 666- 672. DOI: 10.1016/j.jhep.2019.06.002.
[17]	WILSON E, COVERT E, HOFFMANN J, et al. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV(RESOLVE STUDY)[J]. J Hepatol, 2019, 71( 3): 498- 504. DOI: 10.1016/j.jhep.2019.05.021.
[18]	CHEN SS, YAN R, ZHOU K, et al. Efficacy of SOF/VEL/VOX retreatment in DAAs-failed chronic hepatitis C patients with different genotypes[J]. Chin J Clin Infect Dis, 2023, 16( 5): 372- 376. DOI: 10.3760/cma.j.issn.1674-2397.2023.05.006. 陈闪闪, 严蓉, 周克, 等. 索磷布韦/维帕他韦/伏西瑞韦再治疗DAAs治疗失败的不同基因型慢性丙型肝炎患者的疗效分析[J]. 中华临床感染病杂志, 2023, 16( 5): 372- 376. DOI: 10.3760/cma.j.issn.1674-2397.2023.05.006.

Relative Articles

[1]	Linlin WU, Fan ZHANG. Expression of serum 25-hydroxyvitamin D and its clinical significance in patients with nonalcoholic fatty liver disease and obesity[J]. Journal of Clinical Hepatology, 2024, 40(7): 1349-1353. doi: 10.12449/JCH240711
[2]	Wenhao LI, Zhiping LIU, Zhiwei ZHAO, Jinhua ZHANG. Association of 25-hydro xyvitamin D and ferritin with metabolic associated fatty liver disease and fibrosis-4 index[J]. Journal of Clinical Hepatology, 2023, 39(8): 1867-1873. doi: 10.3969/j.issn.1001-5256.2023.08.015
[3]	Peiyao FAN, Fuchuan WANG, Yinjie GAO, Zhiqiang XU, Yi DONG, Jianguo YAN, Lili CAO, Danni FENG, Yanwei ZHONG, Min ZHANG. Value of serum PreS1 in early prediction of HBsAg clearance after IFN-α treatment in children with HBeAg-positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1825-1831. doi: 10.3969/j.issn.1001-5256.2023.08.010
[4]	Quan ZHOU, Jinqiang LI, Xiaowu LI. Influence of vitamin D deficiency on fibrosis-4 index and disease severity in patients with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1293-1298. doi: 10.3969/j.issn.1001-5256.2022.06.015
[5]	Ling LUO, Xianhua LIAO, Bihui ZHONG. Research advances in vitamin D deficiency and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(7): 1641-1645. doi: 10.3969/j.issn.1001-5256.2022.07.034
[6]	Jing LI, Jing XIA, Jie WU. Correlation of the levels of fat-soluble vitamins with biochemical parameters in infants with cholestatic liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2376-2379. doi: 10.3969/j.issn.1001-5256.2021.10.023
[7]	Tingpeng HU, Sudan TANG, Zebo YU. Relationship between vitamin D level in children and adolescents with nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(3): 627-631. doi: 10.3969/j.issn.1001-5256.2021.03.024
[8]	Liu ShenShen, Xing YiQing, Wang Ning, Yu QiaoLing, Ceng LePing. Clinical effect of vitamin E in treatment of nonalcoholic fatty liver disease in children: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1545-1550. doi: 10.3969/j.issn.1001-5256.2020.07.019
[9]	Shen Hong, Hu Meng, Wei ZeHui, Zhang Dong, Zhang JunChang, Tian GuangJun. Bile formation, secretion, and excretion and the pathogenesis of cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(2): 431-437. doi: 10.3969/j.issn.1001-5256.2019.02.043
[10]	Ou WeiJie, Lin YeHong, Zhou Qing, Shang TianYu, Lin Su, Zhu YueYong. Association of vitamin D-related gene polymorphisms with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2019.06.025
[11]	Qu YuLei, Wang YingChun, Wan JinXin. Association of nonalcoholic fatty liver disease with vitamin D and bone mineral density[J]. Journal of Clinical Hepatology, 2019, 35(9): 2021-2025. doi: 10.3969/j.issn.1001-5256.2019.09.027
[12]	Huang CaiZhi, Nie BoLi, Tang Lian, Mo LiYa. Correlation of severity of infantile cholestatic liver disease with serum vitamin D level[J]. Journal of Clinical Hepatology, 2019, 35(8): 1782-1785. doi: 10.3969/j.issn.1001-5256.2019.08.026
[13]	Jiang Tao, Li LiPing, Yi SiSi, Ou YangWenXian, Tan YanFang, Li ShuangJie. Association of perforin and granzyme B with liver injury induced by infectious mononucleosis in Children[J]. Journal of Clinical Hepatology, 2018, 34(9): 1956-1959. doi: 10.3969/j.issn.1001-5256.2018.09.025
[14]	Xu Feng, Liu XiaoLin, Wang Chao, Dai ChaoLiu. Protective effect of prostaglandin E1 pretreatment against liver ischemia-reperfusion injury in rats with cholestasis[J]. Journal of Clinical Hepatology, 2017, 33(5): 899-904. doi: 10.3969/j.issn.1001-5256.2017.05.022
[15]	Zhu BingHua, Xu LieMing. Role of vitamin D and vitamin D receptor in evaluation and treatment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1617-1621. doi: 10.3969/j.issn.1001-5256.2016.08.044
[17]	Yang WeiMin, Xin GuiJie, Ding ShengNan. Levels and clinical significance of serum 25-hydroxy vitamin D in patients with chronic liver disease[J]. Journal of Clinical Hepatology, 2015, 31(5): 754-757. doi: 10.3969/j.issn.1001-5256.2015.05.029
[18]	Wu Qin, Meng FanPing, Ma XueMei, Jin Bo, Shen LiJun, Wu LiBing, Chu JinDong, Lai WenHui, Han JingJing, Li HanWei. Analysis of association between different HCV genotypes and serum interleukin-17, interleukin-6, and vitamin D in patients with HCV-related cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1849-1852. doi: 10.3969/j.issn.1001-5256.2015.11.019
[19]	Lu LunGen. Mechanism of bile secretion, excretion, regulation and cholestasis[J]. Journal of Clinical Hepatology, 2011, 27(6): 570-571+580.
[20]	Qin Hua, Chen Hong. Study on association between vitamin D receptor gene polymorphisms and the chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2009, 25(1): 34-36.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (274) PDF downloads(41)

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure

DOI: 10.12449/JCH241112

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous direct-acting antiviral agent failure

DOI: 10.12449/JCH241112

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content